Short Interest in Citius Oncology, Inc. (NASDAQ:CTOR) Grows By 22.3%

Citius Oncology, Inc. (NASDAQ:CTOR) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totaling 1,202,807 shares, a growth of 22.3% from the December 31st total of 983,877 shares. Based on an average daily trading volume, of 285,256 shares, the days-to-cover ratio is presently 4.2 days. Currently, 1.5% of the company’s stock are sold short. Currently, 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of 285,256 shares, the days-to-cover ratio is presently 4.2 days.

Institutional Trading of Citius Oncology

A number of large investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC purchased a new stake in shares of Citius Oncology during the 3rd quarter worth approximately $15,582,000. Citadel Advisors LLC bought a new position in Citius Oncology during the third quarter valued at $36,000. Bank of America Corp DE grew its holdings in Citius Oncology by 5,256.9% during the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after purchasing an additional 8,411 shares during the period. Jane Street Group LLC purchased a new stake in Citius Oncology in the second quarter worth $465,000. Finally, Geode Capital Management LLC increased its position in Citius Oncology by 179.0% in the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after buying an additional 36,758 shares during the last quarter. Hedge funds and other institutional investors own 70.52% of the company’s stock.

Citius Oncology Stock Performance

CTOR stock opened at $1.15 on Thursday. The company has a quick ratio of 0.11, a current ratio of 0.56 and a debt-to-equity ratio of 0.08. The firm has a market cap of $101.52 million, a PE ratio of -3.38 and a beta of 3.09. The business has a 50 day moving average of $1.14 and a 200-day moving average of $1.53. Citius Oncology has a 12-month low of $0.55 and a 12-month high of $6.19.

Citius Oncology (NASDAQ:CTOR) last posted its quarterly earnings data on Tuesday, December 23rd. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06).

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Citius Oncology in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Citius Oncology presently has a consensus rating of “Hold” and an average price target of $6.00.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.